Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I/II Study of Lintuzumab-Ac225 in Older Patients With Untreated Acute Myeloid Leukemia

NCT02575963 is registered in ClinicalTrials.gov with Actinium Pharmaceuticals as lead sponsor.

NCT NCT02575963
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02575963 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I/II Study of Lintuzumab-Ac225 in Older Patients With Untreated Acute Myeloid Leukemia
Lead sponsor
Actinium Pharmaceuticals
Phase
Phase 1/2
Overall status
Completed
Start date
October 31, 2012
Completion date
May 31, 2020
Enrollment
40 (actual)
Sites
17

Conditions

As the registry lists them; a condition with its own page is linked.

aml